Form 4: Viking Therapeutics CFO Reports Significant Equity Awards

Viking Therapeutics' CFO, Greg Zante, reported the acquisition of substantial equity awards and subsequent tax-related share sales.

Summary

• Greg Zante, Chief Financial Officer of Viking Therapeutics, Inc. (VKTX), reported transactions involving the company's common stock and derivative securities.
• On January 2, 2026, Zante acquired 41,000 shares of common stock through a restricted stock unit (RSU) award under the Issuer's 2024 Equity Incentive Plan, with a vesting schedule of one-third annually from the grant date.
• Also on January 2, 2026, Zante acquired 32,049 shares of common stock from performance restricted stock unit awards, with 33.33% vesting from a January 3, 2023 grant and 1.665% vesting from a January 3, 2025 grant, both upon achievement of non-financial performance goals.
• On January 2, 2026, Zante was granted 91,000 stock options with an exercise price of $35.42, vesting 25% annually from the grant date and expiring on January 2, 2036.
• On January 5, 2026, Zante sold a total of 57,661 shares of common stock in multiple transactions at weighted-average prices ranging from $32.0887 to $34.2364.
• These sales were non-discretionary and solely to satisfy tax withholding obligations related to the vesting of certain RSU awards.
• Following these reported transactions, Zante beneficially owns 189,891 shares of common stock and 91,000 stock options.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The CFO received significant equity awards (RSUs and stock options), indicating continued alignment with shareholder interests and future performance incentives. The sales were non-discretionary for tax withholding, which is a standard and expected practice upon vesting, rather than a discretionary sale indicating a lack of confidence.

Positives

• The acquisition of 41,000 restricted stock units (RSUs) and 32,049 performance-based RSUs aligns the Chief Financial Officer's interests with long-term shareholder value.
• The grant of 91,000 stock options provides further incentive for the CFO to contribute to the company's future growth and performance.
• The vesting of performance restricted stock units indicates the achievement of specified non-financial performance goals.

Negatives

• The sale of 57,661 shares, even for tax withholding purposes, results in a reduction of the Chief Financial Officer's direct beneficial ownership of common stock.

Future Outlook

NA

Industry Context

This filing details routine insider transactions related to executive compensation, which is a common practice across various industries, particularly in biotechnology where equity incentives are a significant component of compensation packages to align management with long-term shareholder value.

Stakeholder Impact

• Shareholders: The significant equity awards granted to the CFO demonstrate continued alignment of management's interests with shareholder value creation. The tax-related sales are a routine part of executive compensation and do not necessarily signal a change in management's outlook.
• Employees: The equity incentive plan and employee stock purchase plan mentioned indicate broad-based equity compensation programs that can impact employee retention and motivation.

Next Steps

• One-third of the 41,000 RSU award shares are scheduled to vest on each one-year anniversary of the January 2, 2026 grant date.
• 25% of the 91,000 stock options are scheduled to vest on each one-year anniversary of the January 2, 2026 grant date.

Key Dates

Keywords

Viking Therapeutics, VKTX, Greg Zante, CFO, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Incentive Plan, Performance Awards, Tax Withholding